BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/12/2024 3:55:58 PM | Browse: 127 | Download: 372
 |
Received |
|
2024-02-27 10:11 |
|
Peer-Review Started |
|
2024-02-27 10:11 |
|
First Decision by Editorial Office Director |
|
2024-04-17 03:28 |
|
Return for Revision |
|
2024-04-17 03:28 |
|
Revised |
|
2024-04-18 00:29 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-04-29 03:03 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-04-29 05:40 |
|
Articles in Press |
|
2024-04-29 05:40 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-06-19 09:40 |
|
Publish the Manuscript Online |
|
2024-07-12 15:55 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Meer M Chisthi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Meer M Chisthi, MBBS, MS, Professor, Surgeon, Department of General Surgery, Government Medical College Pathanamthitta, Aanakuthi, Konni 689691, Kerala, India. meerchisthi@gmail.com |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Lenvatinib; Programmed cell death protein-1 inhibitors; Unresectable hepatocellular carcinoma |
| Core Tip |
Transarterial chemoembolization (TACE) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors presents an encouraging therapeutic approach for unresectable hepatocellular carcinoma (HCC). This triple therapy demonstrates well-tolerated outcomes with a median overall survival of 26.43 mo and a median progression-free survival of 10.07 month. Notably, patients with Barcelona Clinic Liver Cancer B-stage, exhibiting early neutrophil-to-lymphocyte ratio and alpha-fetoprotein responses, show superior clinical outcomes. Understanding these predictive factors can guide treatment decisions and enhance the efficacy of TACE/lenvatinib/PD-1 therapy in unresectable HCC. |
| Publish Date |
2024-07-12 15:55 |
| Citation |
Chisthi MM. Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(7): 2884-2887 |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i7/2884.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i7.2884 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
